{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-342669","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2026-08-10T21:14:42+00:00","discovered_at":"2026-08-10T21:16:00.357510+00:00","generated_at":"2026-08-10T21:16:12.558612+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Erasca appoints Charles Fuchs as President, R&D; adopts 2026 inducement plan","bullets":["Charles S. Fuchs, M.D., M.P.H., appointed President, R&D effective Aug 10, 2026.","Prior roles: CMO at Tubulis (acquired by Gilead), SVP Global Head Oncology at Genentech/Roche, Yale Cancer Center director.","Compensation: $570k base, 45% target bonus, stock options for 1.3M shares vesting over 4 years.","Inducement Plan adopted, reserving 6.2M shares for equity awards without stockholder approval.","Options: 1,278,520 under new Inducement Plan, remainder under 2021 Incentive Plan; exercise price at close on grant date."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-342669","json":"https://secwatch.observer/filing/0001193125-26-342669.json","markdown":"https://secwatch.observer/filing/0001193125-26-342669.md","text":"https://secwatch.observer/filing/0001193125-26-342669.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526342669/0001193125-26-342669-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526342669/eras-20260810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T21:16:12.558612+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}